JP2008518999A5 - - Google Patents

Download PDF

Info

Publication number
JP2008518999A5
JP2008518999A5 JP2007539549A JP2007539549A JP2008518999A5 JP 2008518999 A5 JP2008518999 A5 JP 2008518999A5 JP 2007539549 A JP2007539549 A JP 2007539549A JP 2007539549 A JP2007539549 A JP 2007539549A JP 2008518999 A5 JP2008518999 A5 JP 2008518999A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
phenyl
optionally substituted
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2007539549A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008518999A (ja
Filing date
Publication date
Priority claimed from EP04026441A external-priority patent/EP1655283A1/en
Application filed filed Critical
Publication of JP2008518999A publication Critical patent/JP2008518999A/ja
Publication of JP2008518999A5 publication Critical patent/JP2008518999A5/ja
Abandoned legal-status Critical Current

Links

JP2007539549A 2004-11-08 2005-11-08 11β−HSD1阻害剤 Abandoned JP2008518999A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04026441A EP1655283A1 (en) 2004-11-08 2004-11-08 11beta-HSD1 Inhibitors
PCT/EP2005/011933 WO2006048330A1 (en) 2004-11-08 2005-11-08 11βετα-hsd1 inhibitors

Publications (2)

Publication Number Publication Date
JP2008518999A JP2008518999A (ja) 2008-06-05
JP2008518999A5 true JP2008518999A5 (https=) 2008-12-25

Family

ID=34927280

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007539549A Abandoned JP2008518999A (ja) 2004-11-08 2005-11-08 11β−HSD1阻害剤

Country Status (7)

Country Link
US (1) US20090069323A1 (https=)
EP (2) EP1655283A1 (https=)
JP (1) JP2008518999A (https=)
AT (1) ATE427932T1 (https=)
DE (1) DE602005013812D1 (https=)
DK (1) DK1814846T3 (https=)
WO (1) WO2006048330A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8415354B2 (en) 2004-04-29 2013-04-09 Abbott Laboratories Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US7880001B2 (en) 2004-04-29 2011-02-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US20100222316A1 (en) 2004-04-29 2010-09-02 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
CN101142172A (zh) 2005-01-05 2008-03-12 艾博特公司 11-β-羟甾类脱氢酶1型酶的抑制剂
MX2007008238A (es) 2005-01-05 2007-08-17 Abbott Lab Derivados de adamantilo como inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo 1.
US20090192198A1 (en) 2005-01-05 2009-07-30 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US8198331B2 (en) 2005-01-05 2012-06-12 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US7579360B2 (en) 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US7579504B2 (en) 2005-12-07 2009-08-25 Gilead Sciences, Inc. ABCA1 elevating compounds
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
WO2007138112A2 (en) * 2006-06-01 2007-12-06 Devgen N.V. Compounds that interact with ion channels, in particular with ion channels from the kv family
CA2695613A1 (en) 2006-12-19 2008-06-26 Pharmos Corporation Sulfonamide derivatives with therapeutic indications
TW200845991A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
JP5736098B2 (ja) 2007-08-21 2015-06-17 アッヴィ・インコーポレイテッド 中枢神経系障害を治療するための医薬組成物
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US8927549B2 (en) 2008-11-21 2015-01-06 High Point Pharmaceuticals, Llc Adamantyl benzamide derivatives
ES2350077B1 (es) 2009-06-04 2011-11-04 Laboratorios Salvat, S.A. Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1.
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
CN101838227A (zh) * 2010-04-30 2010-09-22 孙德群 一种苯甲酰胺类除草剂的安全剂
WO2012015715A1 (en) 2010-07-27 2012-02-02 High Point Pharmaceuticals, Llc Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta hsd1 modulators
AU2011313853A1 (en) * 2010-10-11 2013-05-02 Auckland Uniservices Limited Substituted benzamides and their uses
MX386293B (es) 2011-02-18 2025-03-18 Libertas Bio Inc Compuestos de aminoindano y su uso en el tratamiento del dolor.
JP2014521595A (ja) 2011-05-25 2014-08-28 ブリストル−マイヤーズ スクイブ カンパニー 抗アポトーシスBcl阻害剤として有用な置換スルホンアミド
US9073856B2 (en) 2012-01-23 2015-07-07 Eli Lilly And Company Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors
BR112014018712A8 (pt) 2012-01-31 2017-07-11 Lilly Co Eli Derivados de morfolinila úteis como inibidores de mogat-2
AR089771A1 (es) * 2012-01-31 2014-09-17 Lilly Co Eli Derivados de bencil sulfonamida utiles como inhibidores de mogat-2
WO2014028675A1 (en) 2012-08-15 2014-02-20 Endo Pharmaceuticals Inc. Use of aminoindane compounds in treating overactive bladder and interstitial cystitis
US9416138B2 (en) 2012-11-06 2016-08-16 Eli Lilly And Company Benzyl sulfonamide compounds useful as MoGAT-2 inhibitors
PL3303330T3 (pl) 2015-06-03 2019-10-31 Bristol Myers Squibb Co Agoniści 4 - hydroksy - 3 - ( heteroarylo ) pirydyno - 2 - onowi receptora apj do stosowania w leczeniu zaburzeń sercowo-naczyniowych
CA3026149A1 (en) 2016-06-02 2017-12-07 Cadent Therapeutics, Inc. Potassium channel modulators
SI3571193T1 (sl) 2017-01-23 2022-04-29 Cadent Therapeutics, Inc. Modulatorji kalijevega kanalčka
RU2764243C2 (ru) 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
AU2018352142B2 (en) 2017-10-18 2022-08-25 Jubilant Epipad LLC Imidazo-pyridine compounds as PAD inhibitors
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
PT3704120T (pt) 2017-11-24 2024-07-03 Jubilant Episcribe Llc Compostos heterocíclicos como inibidores de prmt5
MX2020009517A (es) 2018-03-13 2021-01-20 Jubilant Prodel LLC Compuestos biciclicos como inhibidores de la interaccion/activacio n de pdl/pd-l1.
CA3116339A1 (en) 2018-10-22 2020-04-30 Cadent Therapeutics, Inc. Crystalline forms of potassium channel modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206219D0 (en) * 2002-03-15 2002-05-01 Ferring Bv Non-Peptide GnRH antagonists
US20060058315A1 (en) * 2002-11-07 2006-03-16 Astrazeneca Ab 2-Oxo-ethanesulfonamide derivates

Similar Documents

Publication Publication Date Title
JP2008518999A5 (https=)
Lamberth et al. Bioactive carboxylic compound classes: pharmaceuticals and agrochemicals
CA2502269A1 (en) Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
AU2018253864B2 (en) Ferroportin-inhibitor salts
JP2006510630A5 (https=)
Emmitte mGlu5 negative allosteric modulators: a patent review (2010–2012)
Karabanovich et al. Development of 3, 5-dinitrobenzylsulfanyl-1, 3, 4-oxadiazoles and thiadiazoles as selective antitubercular agents active against replicating and nonreplicating Mycobacterium tuberculosis
DK2291080T3 (en) Novel modulator of sphingosinphosphatreceptorer
Phillips et al. Discovery of trifluoromethyl (pyrimidin-2-yl) azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure–activity relationships, lead optimization, and chronic in vivo efficacy
CA2646962A1 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
JP2007533741A5 (ja) Bace阻害剤として有用なピロリジン誘導体
CA2570807A1 (en) Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
CA2593264A1 (en) Bicyclic pyrimidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
JP2010520893A5 (https=)
ME02323B (me) Spiro supstituisana jedinjenja kao inhibitori angiogeneze
JP2007507551A5 (https=)
JP2010523653A5 (https=)
RU2009148673A (ru) Производные пиразинона и их применение для лечения легочных заболеваний
IL287159B1 (en) Small molecules agonists for FXR (farnesoid X receptor) and method for their preparation and use
RU2006134004A (ru) Производные гетероариламинопиразола, пригодные для лечения диабета
TW200920361A (en) Compounds useful as medicaments
JP2017508795A5 (https=)
AR077534A1 (es) Derivados de isoxazol, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con el receptor gaba aalfa5
Craig et al. Discovery of DNL343: a potent, selective, and brain-penetrant eIF2B activator designed for the treatment of neurodegenerative diseases
JP6937524B2 (ja) アミド化合物およびその使用